Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India.
Department of Biostatistics, Institute of Liver and Biliary Sciences, New Delhi, India.
Hepatology. 2020 Mar;71(3):1009-1022. doi: 10.1002/hep.30859. Epub 2019 Oct 24.
Transition to chronic kidney disease (CKD) after an episode of acute kidney injury (AKI) is known in patients without cirrhosis. We studied the incidence and risk factors for development of CKD in patients with cirrhosis. Competing risk analysis was performed to identify risk factors for CKD development. Of 818 patients with cirrhosis (age, 50.4 ± 11.8 years; 84% males; Model for End-Stage Liver Disease [MELD], 19.9 ± 9.9), 36% had AKI at enrollment, 27% had previous AKI, and 61% developed new episodes of AKI during the follow-up period. CKD developed in 269 (33%) patients. Serum cystatin C (CysC; subdistribution hazard ratio [SHR], 1.58; 1.07-2.33), episodes of previous AKI (SHR, 1.26; 1.02-1.56), and AKI stage at enrollment (no AKI [SHR, 1] vs. stage 1 [SHR, 3.28; 1.30-8.25] vs. stage 2 [SHR, 4.33; 1.76-10.66] vs. stage 3 [SHR, 4.5; 1.59-12.73]) were identified as baseline risk factors for CKD development. On time-varying competing risk analysis, MELD (SHR, 1.01; 1.00-1.03), number of AKI episodes (SHR, 1.25; 1.15-1.37), and CysC (SHR, 1.38; 1.01-1.89) predicted CKD development. Development of CKD was associated with higher risk of death. Reduction in glomerular filtration rate (GFR) not meeting CKD criteria was observed in 66% of patients with cirrhosis, more so in those with previous AKI episodes and a high CysC level and MELD score. Renal histology, available in 55 patients, showed tubulointerstitial injury in 86%, cholemic nephrosis in 29%, and glomerular changes in 38%. Conclusion: Almost two-thirds of patients with cirrhosis develop episodes of AKI and reduction in GFR; one-third progress to CKD, resulting in adverse outcomes. Higher MELD and CysC levels and number of AKI episodes predict development of CKD in patients with cirrhosis.
在没有肝硬化的患者中,急性肾损伤(AKI)后进展为慢性肾脏病(CKD)是已知的。我们研究了肝硬化患者发生 CKD 的发生率和危险因素。采用竞争风险分析来确定 CKD 发生的危险因素。在 818 例肝硬化患者中(年龄 50.4±11.8 岁;84%为男性;终末期肝病模型评分 [MELD],19.9±9.9),36%在入组时发生 AKI,27%有既往 AKI,61%在随访期间发生新的 AKI 发作。269 例(33%)患者发生 CKD。血清胱抑素 C(CysC;亚分布风险比 [SHR],1.58;1.07-2.33)、既往 AKI 发作次数(SHR,1.26;1.02-1.56)和入组时 AKI 分期(无 AKI [SHR,1]与分期 1 [SHR,3.28;1.30-8.25]与分期 2 [SHR,4.33;1.76-10.66]与分期 3 [SHR,4.5;1.59-12.73])被确定为 CKD 发生的基线危险因素。在时变竞争风险分析中,MELD(SHR,1.01;1.00-1.03)、AKI 发作次数(SHR,1.25;1.15-1.37)和 CysC(SHR,1.38;1.01-1.89)预测 CKD 发生。CKD 的发生与较高的死亡风险相关。在 66%的肝硬化患者中观察到肾小球滤过率(GFR)未达到 CKD 标准的下降,在既往有 AKI 发作和 CysC 水平和 MELD 评分较高的患者中更为明显。在 55 例可获得肾脏组织学的患者中,86%存在肾小管间质损伤,29%存在胆汁性肾病,38%存在肾小球变化。结论:近三分之二的肝硬化患者发生 AKI 和 GFR 下降;三分之一进展为 CKD,导致不良结局。较高的 MELD 和 CysC 水平和 AKI 发作次数预测肝硬化患者 CKD 的发生。